Vitiligo, a common depigmenting skin disorder, has an estimated prevalence of 0.5–2% of
the population worldwide. The disease is characterized by the selective loss of melanocytes …

Vitiligo is the most common depigmenting disorder affecting 0.1%–2% of the population
worldwide. The characteristic white patches result from the selective loss of melanocytes …

Background The treatment of vitiligo can be challenging. Up‐to‐date agreed consensus
recommendations on the use of topical and systemic therapies to facilitate the clinical …

The pathophysiology of vitiligo is becoming increasingly clarified. In non-segmental vitiligo,
early factors include activation of innate immunity, inflammasome activation, oxidative stress …

Vitiligo is a common skin disorder characterized by immune‐mediated destruction of
melanocytes. Non‐segmental vitiligo, the most common clinical subtype, has usually a …

Vitiligo is a chronic autoimmune disease characterized by loss of pigment of the skin,
affecting 0.5–2% of the population worldwide. It can have a significant impact on patients' …

Vitiligo is a multifactorial disease characterized by the loss of skin pigment, which results in
achromic macules and patches. There are currently several medical treatments available …

Vitiligo is a disease characterized by disappearance of melanocytes from the skin. It can
negatively influence the physical appearance of affected individuals, and may profoundly …

Vitiligo is a chronic pigmentary skin disorder that results in white, hypopigmented macules
and patches. It causes a considerable psychological and emotional burden on the affected …

Vitiligo, whose treatment remains a serious concern and challenge, is an autoimmune skin
disease characterized by patches of depigmentation. The increasing application of …